Second dupixent® (dupilumab) phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease

Second dupixent ® (dupilumab) phase 3 e osinophilic e sophagitis t rial to d emonstrate s ignificant d isease i mprovements, u nderscoring r ole of t ype 2 i nflammation in t his c omplex d isease
REGN Ratings Summary
REGN Quant Ranking